{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:31:30Z","timestamp":1791923490087,"version":"4.3.4"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"DOI":"10.1097\/qad.0b013e3283536a93","type":"journal-article","created":{"date-parts":[[2012,3,14]],"date-time":"2012-03-14T09:05:16Z","timestamp":1331715916000},"page":"1105-1113","source":"Crossref","is-referenced-by-count":276,"title":["Adjunctive interferon-\u03b3 immunotherapy for the treatment of HIV-associated cryptococcal meningitis"],"prefix":"10.1097","volume":"26","author":[{"given":"Joseph N.","family":"Jarvis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Rebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertrude Ntombomzi","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tihana","family":"Bicanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Schutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda-Gail","family":"Bekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210130","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1097\/QAD.0b013e3282a4a64d","article-title":"HIV-associated cryptococcal meningitis.","volume":"21","author":"Jarvis","year":"2007","journal-title":"AIDS"},{"key":"R2-6-20210130","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/QAD.0b013e32832be0fc","article-title":"High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out.","volume":"23","author":"Jarvis","year":"2009","journal-title":"Aids"},{"key":"R3-6-20210130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2334-10-67","article-title":"Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases.","volume":"10","author":"Jarvis","year":"2010","journal-title":"BMC Infect Dis"},{"key":"R4-6-20210130","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jinf.2010.03.007","article-title":"Outcomes of cryptococcal meningitis in antiretroviral naive and experienced patients in South Africa.","volume":"60","author":"Jarvis","year":"2010","journal-title":"J Infect"},{"key":"R5-6-20210130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1086\/518607","article-title":"Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole.","volume":"45","author":"Bicanic","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R6-6-20210130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1086\/588792","article-title":"High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial.","volume":"47","author":"Bicanic","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R7-6-20210130","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1086\/420829","article-title":"Recombinant interferon-gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis.","volume":"189","author":"Pappas","year":"2004","journal-title":"J Infect Dis"},{"key":"R8-6-20210130","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/IAI.63.5.1725-1731.1995","article-title":"Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice.","volume":"63","author":"Aguirre","year":"1995","journal-title":"Infect Immun"},{"key":"R9-6-20210130","first-page":"123","article-title":"Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans.","volume":"13","author":"Kawakami","year":"1996","journal-title":"FEMS Immunol Med Microbiol"},{"key":"R10-6-20210130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1365-2249.1999.00955.x","article-title":"Interferon-gamma (IFN-gamma)-dependent protection and synthesis of chemoattractants for mononuclear leucocytes caused by IL-12 in the lungs of mice infected with Cryptococcus neoformans.","volume":"117","author":"Kawakami","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"R11-6-20210130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/13693780410001731510","article-title":"Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans.","volume":"43","author":"Uicker","year":"2005","journal-title":"Med Mycol"},{"key":"R12-6-20210130","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1128\/IAI.00274-06","article-title":"Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain.","volume":"75","author":"Wormley","year":"2007","journal-title":"Infect Immun"},{"key":"R13-6-20210130","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.4049\/jimmunol.178.9.5753","article-title":"Protection from direct cerebral cryptococcus infection by interferon-gamma-dependent activation of microglial cells.","volume":"178","author":"Zhou","year":"2007","journal-title":"J Immunol"},{"key":"R14-6-20210130","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/infdis\/156.2.316","article-title":"Effects of antifungal agents and gamma interferon on macrophage cytotoxicity for fungi and tumor cells.","volume":"156","author":"Perfect","year":"1987","journal-title":"J Infect Dis"},{"key":"R15-6-20210130","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/infdis\/170.5.1331","article-title":"In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis.","volume":"170","author":"Joly","year":"1994","journal-title":"J Infect Dis"},{"key":"R16-6-20210130","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.4049\/jimmunol.174.3.1746","article-title":"IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis.","volume":"174","author":"Siddiqui","year":"2005","journal-title":"J Immunol"},{"key":"R17-6-20210130","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","article-title":"Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.","volume":"363","author":"Brouwer","year":"2004","journal-title":"Lancet"},{"key":"R19-6-20210130","first-page":"25","article-title":"Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients.","volume":"28","year":"2007","journal-title":"South Afr J HIV Med"},{"key":"R20-6-20210130","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America.","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R22-6-20210130","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/604716","article-title":"Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients.","volume":"49","author":"Bicanic","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R23-6-20210130","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/QAD.0b013e32832605fe","article-title":"Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures.","volume":"23","author":"Bicanic","year":"2009","journal-title":"AIDS"},{"key":"R24-6-20210130","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1086\/597262","article-title":"Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa.","volume":"48","author":"Jarvis","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R25-6-20210130","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1086\/657405","article-title":"Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action.","volume":"51","author":"Jarvis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R26-6-20210130","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/QAD.0b013e3283383aeb","article-title":"Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme.","volume":"24","author":"Jarvis","year":"2010","journal-title":"AIDS"},{"key":"R27-6-20210130","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.4049\/jimmunol.142.9.3219","article-title":"Fungicidal activity of IFN-gamma-activated macrophages. Extracellular killing of Cryptococcus neoformans.","volume":"142","author":"Flesch","year":"1989","journal-title":"J Immunol"},{"key":"R28-6-20210130","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1128\/IAI.00297-09","article-title":"Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans.","volume":"77","author":"Voelz","year":"2009","journal-title":"Infect Immun"},{"key":"R29-6-20210130","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2353\/ajpath.2010.090634","article-title":"Pulmonary infection with an interferon-gamma-producing Cryptococcus neoformans strain results in classical macrophage activation and protection.","volume":"176","author":"Hardison","year":"2010","journal-title":"Am J Pathol"},{"key":"R30-6-20210130","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.4049\/jimmunol.174.10.6346","article-title":"Role of IFN-gamma in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis.","volume":"174","author":"Arora","year":"2005","journal-title":"J Immunol"},{"key":"R31-6-20210130","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.4049\/jimmunol.159.11.5528","article-title":"IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production.","volume":"159","author":"Kawakami","year":"1997","journal-title":"J Immunol"},{"key":"R32-6-20210130","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1128\/IAI.70.6.2959-2964.2002","article-title":"Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection.","volume":"70","author":"Herring","year":"2002","journal-title":"Infect Immun"},{"key":"R33-6-20210130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/glia.10093","article-title":"MHC class II-positive perivascular microglial cells mediate resistance to Cryptococcus neoformans brain infection.","volume":"39","author":"Aguirre","year":"2002","journal-title":"Glia"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAD.0b013e3283536a93","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:34:25Z","timestamp":1786048465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-201206010-00006"}},"subtitle":["a randomized controlled trial"],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e3283536a93","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6,1]]}}}